Health Catalyst (HCAT) Stock Analysis & AI Equity Report
Health Catalyst (HCAT) overview
Health Catalyst (HCAT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 311m and operating profit of USD -161m; the year-end share price was 2.39 USD and market capitalisation was USD 172m. Health Catalyst is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Health Catalyst's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Health Catalyst
Health Catalyst provides data and analytics technology and services to healthcare organizations, primarily healthcare providers. Its solution combines a cloud-based data and analytics platform, software applications, and expertise. Clients use these offerings to manage data, generate analytical insights, and support clinical, financial, and operational improvements in their organizations.
Generate the Health Catalyst report
Health Catalyst is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Health Catalyst and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Health Catalyst
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.